UK government

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

This week in Drug Discovery (1 – 5 December) 

News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.  The… Read More

#News

Protesting against health inequalities
#ABPI #NHS #UK government #US government

UK-US trade deal good news for UK life sciences, ABPI says 

The UK-US trade agreement is good news for NHS patients and will support the UK life sciences industry, the Association of the British Pharmaceutical Industry (ABPI) says.  The agreement will ensure that UK pharmaceutical exports to the US continue to face 0% tariffs for three years. In… Read More

#News

Subcutaneous injection
#ABPI #Clinical trial #UK #UK government

Decline in trial recruitment denying patients, ABPI warns 

The decline in commercial clinical trial recruitment is denying patients participation in cutting-edge research, the Association of the British Pharmaceutical Industry (ABPI) has warned.  According to the ABPI’s annual clinical trials report, the number of patients recruited into UK industry clinical trials fell by 25% between 2022/23… Read More

#News

UK and US flags
#ABPI #National Institute for Health and Care Excellence (NICE) #Pharmaceutical industry #UK government

UK-US pharmaceuticals deal supports UK life sciences

A trade deal has been agreed between the UK and the US, which the governments says will secure and expand access to drugs, safeguard the medicines supply chain, and “drive crucial investment while supporting UK patients and industries”.   The deal – part of the UK-US Economic Prosperity Deal – sees the… Read More

#Business & Investment #News #Trending News

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Oncology #Osteosarcoma #UK government

DDW Highlights: 25 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research into bacterial species and diseases broke new ground. Elsewhere, vaccines could… Read More

#Podcasts

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Nuclear medicine #Oncology #Osteosarcoma #UK government

This week in Drug Discovery (17 – 21 November) 

News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW.  This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer.  The top stories:    Medication detrimental to gut microbiome,… Read More

#News

UK
#Cancer research #Nuclear medicine #UK government

UK set to transform nuclear materials into cancer therapies 

Nuclear materials recycled in the UK are set to be used to develop cutting-edge cancer treatments.  A new government-backed project, led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), will use a radionuclide called lead-212 to create treatments known as Targeted Alpha Therapies. The project has… Read More

#Cancer Research #News

#Animal models #In vitro #Innovate UK #UK government

Initiative aims to replace animal models for drug development 

A new UK initiative is aiming to transform human-based research models to provide better understanding of disease and accelerate new medicines.   The UKRI Medical Research Council (MRC), Wellcome and UKRI Innovate UK committed a joint £15.9 million ($20.9 million) investment to develop advanced, specific and highly reproducible… Read More

#Editor's Choice #News

UK financial markets
#AIDs #Malaria #Tuberculosis #UK government

GSK and ViiV Healthcare invest £6 million in Global Fund

Pharmaceutical companies GSK and ViiV Healthcare have invested £6 million ($8 million) in the Global Fund to Fight AIDS, Tuberculosis and Malaria.  The investment will strengthen community-led responses to HIV, tuberculosis (TB) and malaria in lower income countries. The commitment will also be matched by the Gates… Read More

#News

#Association of the British Pharmaceutical Industry #Biopharmaceuticals #Pharmaceutical industry #UK government

UK pharma pricing discussions end in stalemate

The Association of the British Pharmaceutical Industry (ABPI) and the UK government have been unable to reach an agreement on changes to a controversial medicines payment scheme.  In April 2025, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme… Read More

#News #Trending News

Downing Street, London, UK
#Life sciences #Pharmaceutical industry #Politics #UK government

Pharma and UK government continue to debate drug prices

A “battle” between the UK government and the pharmaceutical industry over drug prices has forced the government to delay publication of its plan for the life sciences, according to The Financial Times.  The release of the life sciences review, initially scheduled for the start of this week, was delayed in… Read More

#Business & Investment #News #Trending News

DNA sequencing
#Genetic diseases #Genetics / genomes #Rare diseases #SynaptixBio #UK #UK government

UK genetic screening plan welcomed by biotech

The UK Government has announced that every newborn baby in England will have their genetic code mapped to test for a wide range of conditions, part of a plan that will also see £650m invested in DNA research by 2030.  The Department for Health and Social Care… Read More

#News

#Association of the British Pharmaceutical Industry #Pharmaceutical industry #UK #UK government

UK doubles statutory payment rate on pharma sales

The UK government has doubled the rate that pharmaceutical companies repay on the sales of newer products to the NHS under the statutory scheme for branded medicines to a record 31%.  Following a consultation, the government has decided to raise the statutory scheme payment rate for newer branded medicines from… Read More

#Business & Investment #News

UK financial markets
#Association of the British Pharmaceutical Industry #Investment #Pharmaceutical industry #Research and development #UK #UK government

UK to lose £11bn in pharma R&D investment

The UK could lose out on £11 ($14.8) billion in pharmaceuticals research and development (R&D) investment by 2033, according to WPI Economics.  In the UK, the Voluntary Scheme or VPAG requires companies to pay the Department of Health and Social Care (DHSC) up to a quarter to a third of… Read More

#Business & Investment #News #Trending News

Cancer research lab
#Life sciences #Research and development #UK government #Wellcome Trust

UK data service promises to unlock health data for research

Wellcome has announced plans to partner with the UK Government to establish a new health data research service.  The new service, backed by £100 million from Wellcome and up to £500 million from the UK Government, will give approved researchers a single secure route to health data… Read More

#News